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Executive functionBrain changes reminiscent of Alzheimer disease (AD) have been previously reported in a substantial portion of
elderly cognitive healthy (HC) subjects. The major aim was to evaluate the accuracy of MRI assessed regional
gray matter (GM) volume, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and neuropsy-
chological test scores to identify those HC subjects who subsequently convert to mild cognitive impairment
(MCI) or AD dementia. We obtained in 54 healthy control (HC) subjects a priori defined region of interest
(ROI) values of medial temporal and parietal FDG-PET and medial temporal GM volume. In logistic regression
analyses, these ROI values were tested together with neuropsychological test scores (free recall, trail making
test B (TMT-B)) as predictors of HC conversion during a clinical follow-up between 3 and 4 years. In voxel-
based analyses, FDG-PET and MRI GM maps were compared between HC converters and HC non-converters.
Out of the 54 HC subjects, 11 subjects converted to MCI or AD dementia. Lower FDG-PET ROI values were asso-
ciated with higher likelihood of conversion (p = 0.004), with the area under the curve (AUC) yielding 82.0%
(95% CI = (95.5%, 68.5%)). The GM volume ROI was not a significant predictor (p = 0.07). TMT-B but not the
free recall tests were a significant predictor (AUC = 71% (95% CI = 50.4%, 91.7%)). For the combination of
FDG-PET and TMT-B, the AUC was 93.4% (sensitivity = 82%, specificity = 93%). Voxel-based group comparison
showed reduced FDG-PET metabolism within the temporo-parietal and prefrontal cortex in HC converters. In
conclusion, medial temporal and-parietal FDG-PET and executive function show a clinically acceptable accuracy
for predicting clinical progression in elderly HC subjects.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
The recently proposed research diagnosis of preclinical Alzheimer's
disease is primarily based on brain abnormalities detected by amyloid
PET, FDG-PET, or volumetric MRI in elderly HC subjects (Sperling et al.,
2011). From a clinical point of view, a crucial question is the accuracyerms of the Creative Commons
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lished by Elsevier Inc. All rights reserof such neuroimaging measures for the prediction of clinical progres-
sion to AD dementia in HC subjects. Previous studies showed that
medial temporal lobe FDG-PET hypometabolism was associated with
subsequent conversion to MCI or AD dementia (de Leon et al., 2001;
Mosconi et al., 2008). However, the accuracy of medial temporal lobe
FDG-PET remained below a clinically significant level for the prediction
of progression to MCI (Mosconi et al., 2008). Results from studies
assessing volumetric MRI in elderly HC subjects suggested that regional
GM volume decrease was associated with increased risk to develop AD
dementia (den Heijer et al., 2006; Dickerson et al., 2011). However, the
accuracy of FDG-PET and GM volume for predicting AD dementia in HC
is still unclear, and to our best knowledge, no studies have compared the
utility of FDG-PET and MRI for the detection of preclinical AD so far.
Importantly, although slight cognitive changes have been proposed to
be part of the preclinical stage of AD (Sperling et al., 2011), the diagnos-
tic benefit of combining neuropsychological test and neuroimaging
modalities has not been tested.
Therefore, the major aim of the current study was to assess the
predictive accuracy of regional FDG-PET metabolism, MRI assessedved.
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predicting clinical progression toMCI or ADdementia in elderly HC sub-
jects. For neuropsychological test scores, we used tests of free recall and
the trail making test B (TMT-B) — a measure of executive function —
since these tests were previously shown to be predictive of the clinical
progression from MCI to AD dementia (Ewers et al., 2012).
2. Data and methods
2.1. Subjects
All subjects were recruited within the multicenter Alzheimer's
Disease Neuroimaging Initiative (ADNI, http://www.adni-info.org/)
and all data and scans were obtained from ADNI's publicly available
databank (http://adni.loni.ucla.edu/). In ADNI, the general inclusion
criteria were an age between 55 and 90 years, a modified Hachinski
score ≤ 4, education of at least 6 grade level, and stable treatment of
at least 4 weeks in case of treatment with permitted medication
(for full list see http://www.adni-info.org, Procedures Manual).
A total of 54 HC subjects were included for testing the prediction of
the development of MCI or AD dementia. To be included in the current
study, HC subjects had to have 1) HC diagnosis at baseline, 2) baseline
MRI and FDG-PET scan, 3) conversion to MCI or AD during clinical
follow-up or a clinical follow-up interval of at least 36 months, and
4) a clinical dementia rating (CDR) score = 0 at each follow-up time
point in HC non-converters (see for flow chart Fig. 1). The CDR require-
ment in the HC non-converters was done in order to have a clean
control group to be contrasted against HC subjects who show clinical
progression. Such a study design was considered useful to boost
power for establishing a prediction model that clearly distinguishes
between HC converters and those HC subjects who remain stable. The
requirement of at least 36 months of follow-up time for all HC subjects
was implemented in order to reduce censoring effects.
The ROIs of FDG-PET and GM volume as predictors of clinical
progression were a priori established in a training sample including 78
amnestic MCI with abnormal CSF Aβ1–42 levels and 30 HC subjects
with normal CSF Aβ1–42 levels. The inclusion criteria were 1) diagnosis
of “MCI of the AD type” (Albert et al., 2011) or “prodromal AD”
(Dubois et al., 2007) as recently proposed by the National Institute on
Aging and Alzheimer's Association workgroup (Albert et al., 2011;
McKhann et al., 2011), i.e. amnestic MCI subjects with abnormal CSF
Aβ1–42 levels (b192 pg/ml, henceforth called MCI (Aβ+)). HC subjects
were included if they had CSF Aβ1–42 levels N 192 pg/ml, henceforth
called HC (Aβ−) (Shaw et al., 2009). Due to sample size restriction,Fig. 1. Flow chart of the selection of HC subjects for the test set.the sample of 30 HC (Aβ−) subjects in the training sample included
also 15 HC subjects that were part of the 54 HC subjects (test sample)
in whom the prediction of subsequent conversion to MCI or AD was
tested. Statistical analysis ensured that the overlap between both data
sets did not bias the results (see Statistics section below).
2.2. The ADNI study
ADNIwas launched in 2003 by theNational Institute on Aging (NIA),
the National Institute of Biomedical Imaging and Bioengineering
(NIBIB), the Food and Drug Administration (FDA), private pharmaceuti-
cal companies and non-profit organizations, as a $60 million, 5-year
public–private partnership. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging (MRI), positron emission
tomography (PET), other biological markers, and clinical and neuropsy-
chological assessment can be combined to measure the progression of
mild cognitive impairment (MCI) and early Alzheimer's disease (AD).
The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to
participate in the research — approximately 200 cognitively normal
older individuals to be followed for 3 years, 400 people with MCI to be
followed for 3 years, and 200 people with early AD to be followed for
2 years.
2.3. MRI and FDG-PET acquisition
All MRI data were acquired on 1.5 T MRI scanners using volumetric
T1-weighted sequences to map brain structures, optimized for the
different scanners as indicated at http://www.loni.ucla.edu/ADNI/
Research/Cores/index (Jack et al., 2008).
FDG-PET scans were acquired on multiple scanners of varying reso-
lution. FDG scanswere collected as 6 × 5-min frames beginning 30 min
after injection of approximately 5 mCi of tracer (details at: http://adni.
loni.ucla.edu/wp-content/uploads/2010/09/PET-Tech_Procedures_
Manual_v9.5.pdf). Prior to download, FDG-PET images had been
preprocessed at the University of Berkeley according to a standard
ADNI procedure (frames were co-registered, averaged, oriented along
the anterior–posterior commission line and resliced to a 1.5 mm isotopic
voxel space). The ADNI preprocessing protocol can be found at: http://
adni.loni.ucla.edu/methods/pet-analysis/pre-processing/. In order to
reduce themulticenter variability of the FDG-PET images, correction fac-
tors for image reconstruction were obtained on the basis of scanning a
3D Hoffman phantom object at all participating ADNI sites. This allowed
to derive scanner-specific correction factors. Image reconstruction was
done centrally at the ADNI PET imaging core laboratory (for details see
(Joshi et al., 2009)).
2.4. Spatial normalization of MRI and FDG-PET scans
The T1 MRI scans were segmented and the resulting GM partitions
were spatially normalized using high-dimensional large-deformation
diffeomorphic registration as implemented in the DARTEL tool of
SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/) (Ashburner, 2007).
In the first step, the MRI scans were segmented into GM, white matter,
and CSF partitions (Ashburner and Friston, 2005). Rigid body transfor-
mation was applied in order to bring GM segments into approximate
alignment. The estimation of the non-linear spatial normalization
parameters was calculated in iterative steps of the template generation.
Within each of 6 successive cycles, an average of the GM tissue class
images was generated and all GM maps were spatially normalized
using a linear set of basis functions, where the optimization of the pa-
rameter estimates followed the Levenberg–Marquardt (LM) algorithm
as the minimum energy optimization procedure (Ashburner, 2007).
The normalization parameters were applied to the GM images. In the
next cycle, the GM images that had been normalized during the first
step were averaged and once more subjected to the spatial normaliza-
tion procedure. This cycle was iterated 6 times, successively relaxing
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the spatial resolution of the template became crisper (see also manual
of SPM 8 at http://www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf). In the
final step, the custom GM template was registered onto the ICBM GM
template in MNI space included in the SPM8 package and combined
with the non-linear flow fields estimated during the diffeomorphic nor-
malization procedure described above. GM segments were modulated
(i.e. multiplied by the Jacobian determinants of the spatial transforma-
tion) in order to yield a GM concentration in proportion to the dilation
or contraction a voxel underwent during spatial normalization. The
total intracranial volume (ICV) was estimated as the sum of the GM,
WM and CSF tissue class images in native space obtained during the
spatial normalization procedure (described above). For FDG-PET, each
FDG-PET scan was coregistered to the individual's corresponding GM
segment in native space. The spatial normalization parameters that
had been estimated on the basis of the MRI images via DARTEL were
subsequently applied to the coregistered FDG-PET images so that both
the GMmaps and the FDG-PET images were in MNI space.
For intensity normalization of the FDG-PET scans to the pons, amask
was manually drawn onto the GM template in MNI space, using a 3-D
display in the programMIPAV (http://mipav.cit.nih.gov/). The binarized
mask was multiplied with each spatially normalized FDG-PET image to
calculate the average FDG-PET within the pons region. Each voxel of a
subject's FDG-PET image was subsequently divided by the individual
average FDG-PET value of the pons.
Correction for partial volume effects (PVEs) was done using the
geometric transfer matrix (GTM) method (Rousset et al., 1998) as
implemented in the software program PMOD (PMOD Technologies
Ltd, Zurich, Switzerland). Briefly, the spill-over effects between the dif-
ferent brain compartments are estimated by convolving binarized
voxels of interest (GM vs. background) with the point spread function
to derive the weights of the spill-over effects. Based on these weights,
the PVE corrected FDG-PET images were estimated (http://www.
pmod.com/technologies/pdf/doc/PNEURO.pdf).
All GM and FDG-PET images were finally spatially smoothed with a
Gaussian kernel at 8 mm FWHM.
2.5. Construction of FDG-PET and GM ROIs
Voxel-based ANCOVAs were used to compare group differences
between HC (Aβ−) and MCI (Aβ+) subjects (training sample), using
group as the independent variable, and in the case of GM maps, ICV as
an additional covariate. Potentially confounding variables including age,
gender, and education did not differ between the HC (Aβ−) and MCI
(Aβ+)groups (Supplementary Table 1), andwere therefore not included
as covariates in the voxel based regression analyses. TheMMSE scorewas
lower (t = −4.9, df = 106, p b 0.001) and ApoE ε4 genotype wasmore
frequent in the MCI (Aβ+) compared to the HC (Aβ−) groups
(χ2 = 23.3, df = 1, p b 0.001). In addition to CSFAβ1–42 (group selection
variable), CSF total tau (Welch two-sample t-test: t = −5.9, df = 105,
p b 0.001) and CSF p-tau181 (Welch two-sample t-test: t = −7.6,
df = 96, p b 0.001) differed between groups (see also Supplementary
Table 1).
For voxel-based comparison of the FDG-PET and GM maps, the
statistical parametric maps of the t-scores were thresholded at the
voxel-level at p = 0.001 (uncorrected), with the cluster extent thresh-
old set to the number of expected voxel per cluster (k), including
k = 624 (for FDG-PET) and k = 254 (for GM maps).
Results showed significantly lower FDG-PET metabolism primarily
within the medial temporal and medial–parietal brain regions in MCI
(Aβ+) compared to HC (Aβ−) (Supplementary Table 2, Supplementary
Fig. 1A). For GM differences, voxels with significantly reduced GM vol-
ume (MCI (Aβ+) b HC (Aβ−)) clusteredwithin the inferior andmedial
temporal lobe (Supplementary Table 3, Supplementary Fig. 1B). No brain
region showed significantly larger FDG-PET metabolism or GM volume
in MCI (Aβ+) compared to HC (Aβ−). Clusters of significant groupdifferences of FDG-PET or GM volume were binarized to create a single
ROI mask for each modality. FDG-PET and GM volume within the ROI
masks were subsequently obtained from the baseline FDG-PET and GM
maps of each of the 54 HC subjects.
2.6. Neuropsychological tests
Episodic memory was assessed by the Rey Auditory Verbal Learning
Test (RAVLT), which includes a list of 15 words to be recalled immedi-
ately after each of the 5 verbal presentations and after a 30-min delay
(Rey, 1964). A test of frontal lobe functions included the trail making
test B (TMT-B, score: total number of seconds to complete the test)
(Reitan and Wolfson, 1985).
2.7. Statistics
“Conversion”was defined as a change in diagnosis fromHC toMCI or
AD dementia during the follow-up in the 54 HC subjects (test set).
Logistic regression analyses were used to predict conversion status
(non-converter vs. converters). The predictors included baseline FDG-
PET ROI (both uncorrected or corrected for PVE), GM volume ROI,
RAVLT immediate free recall, RAVLT delayed free recall, and the TMT-
B test. Separate logistic regression models were constructed for each
predictor and significant predictors were subsequently combined in a
final model to test additive effects. Each model was corrected for age,
gender, and ApoE genotype (ε4 allele carriers vs. ε4 allele non-
carriers). Normal distribution of each predictor was tested by Shapiro–
Wilks tests, and — in case of non-normal distribution — the variables
were rank transformed. All predictors were transformed into z-scores
before entering them into the logistic regression model to yield better
comparison of the regressionweights between predictors. ROC analyses
for significant predictors were conducted, using bootstrapping with
n = 1000 resampling iterations to estimate the area under the curve
(AUC) and the specificity at a fixed sensitivity of 80%. The bootstrapped
95% confidence intervals (95% CI) of the AUC and specificity are report-
ed. In order to examine the robustness of the results, the logistic regres-
sion analyses for the prediction of conversion in the 54HC subjectswere
repeated, now excluding those 15HC subjectswhohad also been part of
the training sample for the establishment of the ROIs (see above
“Construction of FDG-PET and GM ROIs”). All of these analyses were
done with the program R (version 2.12.1, www.r-project.org).
Voxel-based comparisons of FDG-PET and GM maps between HC
converters vs. non-converters were conducted through ANCOVAs,
controlled for age (that differed significantly between converters and
non-converters). For the voxel-based group comparison of GM volume,
the ICV was an additional covariate in the regression analyses. The sta-
tistical parametric maps were thresholded at p = 0.001 (uncorrected
at voxel level), where only clusters exceeding the expected number of
voxels per cluster (cluster extent threshold) were reported. Voxel-
wise maps of the effect size d (Cohen, 1992) were computed to display
group differences unbiased by sample size.
3. Results
3.1. Conversion from HC to MCI or AD dementia
The descriptive statistics of the HC converters and HC non-
converters are displayed in Table 1. Over a time interval of 54 months,
11 out of 54 HC subjects progressed to MCI or AD (MCI: n = 9, AD
dementia: n = 2). All of the 11 subjects had converted after 3 years,
except for one subject (time to conversion = 4 years). For the non-
converters, all of the subjects had been assessed at least for 3 years of
clinical follow-up duration. Nineteen out of 43 non-converters (44%)
had also been assessed after at least 4 years. HC converters were signif-
icantly older than HC non-converters (t = −3.5, df = 16.6, p =
0.002).
Table 1
Demographic, clinical and biomarker statistics in HC converters and HC non-converters. The mean and standard deviation (SD) are indicated where appropriate.
Group N Age (yrs) Sex (f/m) Edu (yrs) ApoE ε4 (+/−) MMSE TMT-B (in sec.) Recall immed. Recall del.
HC converter 11 78.9 (3.7) 5/6 16.3 (2.9) 4/7 29.0 (0.8) 141.2 (45.1) 40 (10.4) 5.6 (4.4)
HC non-converter 43 74.3 (4.6) 15/28 16.6 (3.0) 12/31 28.4 (1.2) 111.2 (32.3) 44.1 (10.1) 7.7 (4.1)
ApoE (+) = ApoE ε4 carriers, ApoE (−) = ApoE ε4 non-carriers, Edu = education, Recall immed. = immediate free recall, Recall del. = delayed free recall, yrs = years, f = female,
m = male, sec. = seconds.
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Logistic regression analyses showed that the FDG-PET ROI (including
medial temporal and parietal brain regions) was a significant predictor
of HC conversion (B = −1.4 z-core units, SE = .5, p = 0.006), inde-
pendent of age, gender, and ApoE ε4 status. The results of the ROC anal-
ysis are shown in Table 2 and Fig. 2. Specifically, the ROC analysis for the
age-adjusted FDG-PET ROI yielded an AUC of 77.8% (95% CI = (62.2%,
93.6%)). The bootstrapped median specificity was 51.2% (95%
CI = (27.9%, 93%)) at a fixed sensitivity of 80%. The FDG-PET ROI after
PVE correction remained a significant predictor of conversion (B =
1.4 z-score units, SE = .5, p = 0.004), with the AUC remaining virtual-
ly the samewhen compared to the FDG-PETmodel without PVE correc-
tion: AUC = 80.3% (95% CI = (66.2%, 94.5%)).
The ROI of GM volume (medial temporal lobe regions) was not a
significant predictor of conversion (p = 0.07). Because the significance
threshold wasmissed by a small margin, the ROC analysis was comput-
ed nevertheless. At a sensitivity of 80%, the mean specificity of the GM
volume ROI was below 50%.
For neuropsychological tests, the logistic regression analyses
showed that TMT-B test scores discriminated HC converters from HC
non-converters (B = 0.88 z-score units, SE = 0.4, p = 0.03), adjusted
for age, gender, and ApoE ε4 genotype. The tests of free recall were
not significant predictors. ROC analysis showed for age-adjusted TMT-
B scores an AUC of 71% (95% CI = 50.4%, 91.7%). At a fixed sensitivity
of 80%, the median specificity was 34.9% (95% CI = 9.3%, 95.3%). In a
combinedmodel, TMT-B test scores significantly added to the predictive
accuracy of the FDG-PET ROI (TMT-B: B = 1.8 z-score units, SE = 0.7,
p = 0.01, FDG-PET ROI: B = −2.3 z-score units, SE = 0.8, p =
0.005). The AUC of the combined model of FDG-PET plus TMT-B in-
creased to 89.4% (95% CI = 79.9%, 98.9%). The sensitivity was 81.8%
and the specificity was 79.1% for the combined model.
When repeating the regression analyses excluding those 15 HC
subjects who had been also part of the training sample, the result
pattern remained the same for all analyses (data not shown), indicating
that the results were not influenced by the partial overlap between
training and test samples.
CSF biomarkermeasurementswere available in a subset of the 54HC
subjects including 7 HC converters and 22 HC non-converters. Abnor-
mal CSF Aβ1–42 levels (b192 pg/ml) (Shaw et al., 2009) were present
in 5 (71%) HC converters and 9 (41%) HC non-converters. Abnormal
CSF p-tau181 levels (N23 pg/ml) (Shaw et al., 2009) were present in 3
(75%) HC converters and 6 (27%) of HC non-converters.Table 2
Specificity at a fixed sensitivity of 80% and AUC for the classification of HC converter vs.HC
non-converter.
Predictor % AUC (95% CI) % specificity
(at 80% sensitivity)
FDG-PET ROI 77.8 (62.2, 93.6) 51.2
PVE corrected FDG-PET ROI 80.3 (66.2, 94.5) 67.4
TMT-B 71 (50.4, 91.7) 34.9
Combined FDG-PET & TMT-B 89.4 (79.9, 98.9) 79.1a
Combined PVE corrected FDG-PET & TMT-B 92 (84.2, 99.8) 80.7a
a Exact sensitivity was 81.8%.3.3. Voxel based comparison of FDG-PET and MRI between HC converters
and HC stable
In the voxel-based comparison of FDG-PET, HC converters showed
hypometabolism within the areas of the medial frontal gyrus and the
temporo-parietal brain areas (Fig. 3, for cluster coordinates see Supple-
mentary Table 4). No brain areas showed increased FDG-PET in HC con-
verters when compared to HC stable subjects. The comparison of GM
volume between HC converters and HC non-converters produced no
significant clusters of group differences.
Lastly, we mapped the effect size d of FDG-PET and GM volume for
the comparison betweenHC converters andHCnon-converterswithout
thresholding the maps on the basis of p-values. Visual inspection of
the effect size maps shows that the effect sizes of group differences
(i.e. lower FDG-PET in HC converters) are highest within the temporal,
frontal, and parietal brain areas (Fig. 4A), and are higher in most brain
areas when compared to the group difference in GM volume (Fig. 4B).
For GM volume, the highest effect sizes of decreased GMvolumewithin
the HC converters group are primarily centered within the medial
temporal lobe.
4. Discussion
Our findings of the prediction of the conversion from HC toMCI and
AD dementia based on the a priori determined FDG-PET ROI (located in
the medial temporal and parietal lobes) is consistent with previous
studies showing that medial temporal and parietal FDG-PET wasFig. 2.ROC curves for the classification of HC converters vs.HCnon-converters based on the
FDG-PET ROI (green), TMT-B test (blue) and the combination of both FDG-PET ROI and
TMT-B (red). The AUC values are indicated in Table 2.
Fig. 3. Projection of voxel-based t-statistic map onto axial brain slices. Yellow designates t-values for significantly higher FDG-PET in HC non-converters compared to HC converters. The
opposite contrast (HC converters N HC stable) was not significant.
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campal/entorhinal FDG-PET was sensitive to preclinical AD (de Leon
et al., 2001; Mosconi et al., 2008). These regions of reduced FDG-PET
in medial temporal and medial parietal brain areas can be considered
a subset of those temporo-parietal areas (i.e.medial and lateral parietal
lobes &medial temporal lobes) that are typically affected in AD demen-
tia (Mosconi, 2005). Whereas we found a predictive effect of the
FDG-PET ROI on subsequent clinical progression,we did not detect a sig-
nificant predictive value of the medial temporal GM volume ROI. The
findings are in line with MRI studies reporting that baseline total GM
or medial temporal GM in HC subjects did not predict global cognitive
decline (Jagust et al., 2006) or progression to MCI or AD (Rusinek
et al., 2003). However, the results are in disagreement with other stud-
ies suggesting thatmedial temporal GMvolume is affected in preclinical
AD (Chiang et al., 2011; Dickerson et al., 2012). In particular, recent
studies showed that a summary measure of cortical thickness ROIs in-
cluding several temporal, parietal and prefrontal brain regions showed
predictive value for the classification of subjects who subsequently
converted to AD dementia (Dickerson et al., 2011). Inconsistencies
between the current and previous findings might be explained by
methodological differences including differences in cortical thickness
vs. morphometric measures (Hutton et al., 2009; Winkler et al., 2010),
or a more advanced state of disease severity of HC subjects included in
those studies which detected gray matter atrophy at the preclinical
stage (Dickerson et al., 2011). The most parsimonious explanation is,
however, that the subtle gray matter differences were already present
but remained below the significance threshold in the current study.
The examination of the effect size maps of gray matter volume differ-
ences confirmed that reductions in gray matter volume were mostly
confined to the medial temporal lobe, which is in general agreement
with previous reports of voxel-based analysis showing that GM volume
decreases exclusively within the medial temporal and angular gyrus in
HC subjects who later convert to MCI (Smith et al., 2007). Importantly,
the effect sizemap confirmed that FDG-PET hypometabolismwaswide-
ly spread out within the gray matter brain areas, supporting the notion
that FDG-PET was more affected compared to GM volume in subjects
who showed clinical worsening that may correspond to preclinical AD.
For neuropsychological tests, the TMT-B test but not measures of
episodic memorywere predictive of clinical progression.We previously
reported that the TMT-B test outperformed other neuropsychological
tests including tests of free recall, category fluency, digit span, and theBoston naming test for predicting conversion fromMCI to AD dementia
(Ewers et al., 2012). Together with the previous findings, the current
results suggest that TMT-B test might reflect cognitive function that is
affected early in the course of AD. The TMT-B test is thought to be amea-
sure of visual attention and cognitive flexibility associated with frontal
and parietal lobe function (Zakzanis et al., 2005). It is not known exactly
which functional and structural brain changes in AD underlie the cogni-
tive performance changes on the TMT-B test early in the course of AD.
However, from a clinical point of view, the combination of the TMT-B
and regional FDG-PET provides high sensitivity and specificity for the
detection of clinical worsening in elderly HC subjects — possibly at an
early stage of AD dementia. It should be noted that no systematic
screening of a large range of neuropsychological tests or biomarkers
candidates was done in the current study. Thus, neuropsychological
tests or biomarkers other than those tested here may be relevant as
well (Chary et al., 2013; Condret-Santi et al., 2013; Sperling et al.,
2011; Tondelli et al., 2012). In the current study, some of the a priori
selected predictors that were previously shown to be sensitive to pro-
dromal AD (Ewers et al., 2012) were confirmed to be successful for
the prediction of clinical progression inHC subjects. It is for larger future
studies to validate the current results and define a potentially extended
test set of best predictors of preclinical AD. Apart from the current objec-
tive measures of neuropsychological ability, subjective memory com-
plaints have previously been shown to be a potential predictor of
subsequent memory decline (Chamberlain et al., 2011; Scheef et al.,
2012) in elderly cognitively normal subjects andmay be tested in future
studies as well.
For the interpretation of the current results, it is important to note
that not all HC subjects who converted to MCI may eventually progress
to AD dementia. Compared to the HC non-converters, a higher propor-
tion of HC converters showed abnormal measures on primary AD pa-
thology as measured by CSF Aβ and p-tau181 levels that were available
in a subset of the patients, supporting the notion that the HC converters
were afflicted by preclinical AD. The development to AD dementia need
to be confirmed, however, in future follow-upswithin the ADNI project.
It should also be noted that the subset of 54 HC subjects represents a
subsample of the overall total of 229 HC subjects assessed in ADNI I.
The sample size reduction was majorly due to the ADNI I study design,
where a subset of the 229 HC subjects received FDG-PET at baseline.
For the current study further requirements included follow-up duration
(N3 years) and a CDR of 0 for the HC non-converters. We considered
Fig. 4.Maps of effect size d for the group comparison of HC converter vs. HC non-converter are superimposed onto axial brain slices for FDG-PET (A) and MRI gray matter (B). Red colors
indicate a positive effect size, i.e. HC non-converter N HC converter, the bluish colors indicate the opposite effect. (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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51M. Ewers et al. / NeuroImage: Clinical 4 (2014) 45–52these requirements useful in order to be able to clearly define a control
group to establish a sensitive prediction model of preclinical AD.
Increased brain Aβ PET binding in the brain has previously been
shown to be predictive for the conversion to AD dementia in MCI sub-
jects and may also predict clinical progression at the preclinical stage
of AD (Nordberg et al., 2013; Okello et al., 2009). Thus the question
needs to be addressed to what extent the current markers add to mea-
sures of primary pathology (tau or Aβ) to the detection of preclinical AD
(Desikan et al., 2012; Prestia et al., 2013).
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